These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37746740)

  • 1. Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4.
    Jiang P; Chen T; Chu LF; Xu RP; Gao JT; Wang L; Liu Q; Tang L; Wan H; Li M; Ren HC
    Expert Opin Drug Metab Toxicol; 2023; 19(10):721-731. PubMed ID: 37746740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
    Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
    AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
    Youdim KA; Zayed A; Dickins M; Phipps A; Griffiths M; Darekar A; Hyland R; Fahmi O; Hurst S; Plowchalk DR; Cook J; Guo F; Obach RS
    Br J Clin Pharmacol; 2008 May; 65(5):680-92. PubMed ID: 18279465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
    Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice.
    Miyake T; Mochizuki T; Nakagawa T; Nakamura M; Emoto C; Komiyama N; Hirabayashi M; Tsuruta S; Shimojo T; Terao K; Tachibana T
    Br J Pharmacol; 2024 Apr; 181(7):1091-1106. PubMed ID: 37872109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
    Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method.
    Umehara KI; Huth F; Gu H; Schiller H; Heimbach T; He H
    Drug Metab Pers Ther; 2017 Dec; 32(4):191-200. PubMed ID: 29176011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
    Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
    Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.